XOMA (NASDAQ:XOMA) Upgraded at StockNews.com

StockNews.com upgraded shares of XOMA (NASDAQ:XOMA) from a sell rating to a hold rating in a research note released on Tuesday.

Separately, HC Wainwright decreased their price target on XOMA from $123.00 to $104.00 and set a “buy” rating for the company in a report on Monday, February 3rd.

XOMA Price Performance

Shares of XOMA opened at $27.10 on Tuesday. The company has a current ratio of 7.52, a quick ratio of 7.52 and a debt-to-equity ratio of 1.28. The firm’s fifty day simple moving average is $26.91 and its 200-day simple moving average is $27.97. The firm has a market capitalization of $319.24 million, a price-to-earnings ratio of -7.79 and a beta of 0.90. XOMA has a twelve month low of $19.50 and a twelve month high of $35.00.

Insider Activity

In related news, major shareholder Bvf Partners L. P/Il sold 500,742 shares of the business’s stock in a transaction on Friday, January 24th. The shares were sold at an average price of $26.10, for a total value of $13,069,366.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 7.20% of the company’s stock.

Institutional Trading of XOMA

Hedge funds and other institutional investors have recently made changes to their positions in the company. Charles Schwab Investment Management Inc. grew its stake in XOMA by 5.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 23,113 shares of the biotechnology company’s stock worth $607,000 after buying an additional 1,276 shares during the last quarter. Los Angeles Capital Management LLC acquired a new stake in shares of XOMA in the fourth quarter valued at approximately $206,000. New York State Common Retirement Fund grew its position in shares of XOMA by 51.2% during the fourth quarter. New York State Common Retirement Fund now owns 2,362 shares of the biotechnology company’s stock worth $62,000 after acquiring an additional 800 shares during the last quarter. Rhumbline Advisers increased its holdings in shares of XOMA by 18.1% in the 4th quarter. Rhumbline Advisers now owns 11,065 shares of the biotechnology company’s stock valued at $291,000 after acquiring an additional 1,699 shares during the period. Finally, Barclays PLC raised its position in XOMA by 300.7% in the 3rd quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock valued at $298,000 after purchasing an additional 8,447 shares during the last quarter. Institutional investors and hedge funds own 95.92% of the company’s stock.

XOMA Company Profile

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.